In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Revlon targeted by class action

This article was originally published in The Rose Sheet

Executive Summary

Class action filed by Berger & Montague, P.C. would include all shareholders who participated in Revlon's exchange offer of Sept. 24, 2009, converting shares of Class A common stock for preferred stock. Following that transaction, Revlon posted "stellar" financial results for its fiscal 2009 third quarter, ended Sept. 30, "causing the company's Class A common stock price to rise by over 300%," according to Berger & Montague's recent release. Stockholders were not apprised of company's expected positive results, though they were entitled to such information before deciding whether to exchange stock, the law firm says. Investors interested in acting as lead plaintiff in the suit are encouraged to contact Berger & Montague, whose office of approximately 70 attorneys "[has] recovered several billion dollars for consumers and investors" as a "pioneer in class action litigation." Revlon's controlling stockholders MacAndrews & Forbes Holdings Inc. proposed to buy out minority stakeholders in spring 2009 (1"The Rose Sheet" April 27, 2009)

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016659

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel